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Introduction
Transformation of the uterine spiral arteries during the first twenty weeks of gestation ensures that a constant supply of blood is delivered to the developing placenta, at an optimal rate of flow [1] [2] [3] . This allows the placenta to meet an increasing requirement for nutrients and oxygen, and enables the developing fetus to attain its growth potential. The remodelling process leads to vessel dilatation, loss of spirality and decreased vasoactivity, allowing a non-pulsatile, low pressure supply of blood to be delivered to placental villi at the maternofetal interface. Early alterations in arterial structure include endothelial vacuolation, hypertrophy of vascular smooth muscle cells (VSMC) and disruption of medial smooth muscle layers, which occur in the absence of fetal-derived trophoblast and correlate with perivascular accumulation of macrophages and uterine natural killer (uNK) cells 4, 5 . Following colonisation of the uterine decidua and myometrium by extravillous cytotrophoblast (EVT), endothelial cells and VSMC are lost from the arterial wall and replaced by trophoblast embedded in a fibrinoid matrix.
Remodelling is regulated in a spatial and temporal manner, such that the successive steps of trophoblast adherence, intravasation, fibrinoid deposition and mural incorporation are effected without any loss in vessel integrity. A complex and highly orchestrated combination of vascular cell apoptosis, dedifferentiation and matrix breakdown is probably required to achieve this alteration in vessel wall structure [5] [6] [7] [8] [9] .
Two distinct populations of EVT originate from anchoring placental villi and contribute to vessel transformation 10, 11 . Interstitial EVT invade the uterine wall, migrating through the decidua and myometrium to adopt a perivascular position. Endovascular EVT enter the lumen of the spiral arteries and migrating as far as the first third of the myometrium, colonising the arterial wall from within. Impaired arterial remodelling is distinguished by shallow EVT invasion, decreased numbers of EVT and the persistence of muscular, narrow-bore arteries, and is associated with second trimester miscarriage 12 , preterm labour 13 , preeclampsia 14 and fetal growth restriction 15 .
To effect a permanent increase in vessel diameter it is crucial that elastin fibres within each artery are catabolised, eliminating their capacity for stretch and recoil. Myometrial segments of the spiral arteries possess an internal elastic lamina (IEL), and the musculo-elastic media of both decidual and myometrial arteries is rich in elastic fibres 16, 17 . During pregnancy, EVT traverse the IEL during mural incorporation 18 , thus it is highly likely that they possess elastase activity: indeed, first trimester EVT synthesize and secrete the elastolytic proteases matrix metalloproteinase-2 (MMP-2), MMP-7, MMP-9, cathepsin B and cathepsin L 19, 20 .
Although both uNK cells and macrophages produce enzymes capable of elastolysis 5 , uNK cells are not abundant in myometrium 21 , and elastin breakdown is associated with the presence of endovascular EVT 17 , rather than macrophages 22 . Previous studies have demonstrated that the availability of nitric oxide (NO) can influence protease expression and activity [23] [24] [25] [26] , and we have shown NO to be an important regulator of trophoblast function [27] [28] [29] .
As dysregulation of NO production has been implicated in the pathogenesis of pre-eclampsia and IUGR [30] [31] [32] , NO availability may regulate the process of arterial remodelling by controlling trophoblast elastolysis.
Rodent models of atherosclerosis have highlighted a role for VSMC-derived cathepsins as mediators of IEL breakdown during lesion formation 33 , demonstrating that the arterial wall may be a potential source of elastases. Similarly, caspase-2, -3 and -7 derived from apoptotic VSMC have been implicated as mediators of elastin breakdown 34 . Thus, during the process of spiral artery transformation, resident VSMC may also be stimulated to produce elastase (s) in response to pregnancy hormones, trophoblast invasion or soluble factors released by cells within the placental bed. In this study we have investigated the origin and identity of the proteases involved in mediating elastin breakdown during spiral artery remodelling.
Materials and methods

Reagents
Caspase inhibitor zVAD-fmk, cathepsin inhibitor Z-Phe-Gly-NHO-Bz-pOMe, Calbiochem 
Vessel explant model
Dissection and perfusion of spiral arteries was performed as previously described cleavage by elastase this substrate absorbs at 405nm. After addition of 5µl of glacial acetic acid, the A405 of each sample was determined and compared to a calibration curve prepared using porcine pancreatic elastase. The protein concentration of each sample was measured using a Biorad protein assay with a standard curve prepared using bovine serum albumin. Elastase activity data was expressed as activity per mg of protein.
Time lapse microscopy
Proliferating SGHPL-4 and HASMC (0.25X10 6 cells) were seeded into 6 well plates and left to adhere. Following addition of elastin (1mg/ml), NNGH (50µM) and L-NAME (5mM), elastin uptake was monitored by time-lapse microscopy using an Olympus IX70
inverted fluorescence microscope with a motorised stage and cooled CCD camera (Hamamatsu model C4742-95) enclosed in a humidified chamber at 37°C with 5% CO 2 in air, as described previously 37 . Images were taken at 15 min intervals and time-lapse sequences were analysed using ImagePro Plus (Media Cybernetics, Silver Spring, MD, USA). Fifteen cells were scored from each field of view (wells were analysed in triplicate) and the time at which a cell took up a fragment of elastin was recorded.
RNA extraction, cRNA synthesis, and gene expression profiling EVT outgrowths from villous explants cultured on Matrigel (obtained from six different first trimester placentas, 7-10 weeks gestation) were isolated and total RNA was extracted as previously described 38, 39 . RNA integrity was checked by agarose gel electrophoresis and with the Agilent Bioanalyzer 2100 (Agilent Technologies, Inc., Palo Alto, CA). 5µg of total RNA were then used for GeneChip analysis. Preparation of cRNA, hybridization to human U133 GeneChips, and scanning of the arrays were performed according to the manufacturer's protocols (Affymetrix Inc., Santa Clara, CA), as previously described 40 .
Statistics
Statistical analyses were performed using GraphPad Prism software version 4 (GraphPad Software, San Diego, CA, USA). Non-parametric data was represented by median and range, and was analysed using a Kruskal-Wallis tests with appropriate post-hoc analysis. Data represent at least 3 independent experiments. Significance was taken as p<0.05.
Results
Elastase activity in trophoblasts is attributed to caspases and matrix metalloproteinases
To investigate the contribution of trophoblast-derived elastases to arterial remodelling, we analysed intracellular and total elastase activity of human first trimester CTB. When cultured with Congo red-labelled elastin, CTB were observed to engulf and degrade elastin fibres ( Figure 1A ). CTB exhibited detectable intracellular elastase activity, which was significantly reduced by a broad spectrum caspase inhibitor, but only when CTB were isolated from placentas of less than 9 weeks of gestation (P<0.05; Figure 1B supernatants demonstrated marked elastase activity, which was completely inhibited by the broad spectrum MMP inhibitor NNGH (P<0.05, Figure 1D , E). As the MMP inhibitor had no effect on intracellular elastase activity, the MMP activity in the CTB supernatants must be attributable to membrane-associated elastases. Elastase activity in CTB conditioned medium was below the level of detection of this assay (data not shown).
To investigate the kinetics of elastin breakdown, SGHPL-4 cells were incubated with elastin and monitored at 15 minute intervals for 24h by time lapse video-microscopy. of controls after 6h and 81% after 24h (P<0.05; Figure 2C ). It has previously been shown that in some cell types, the availability of nitric oxide (NO) can influence the expression and activity of certain proteases [23] [24] [25] [26] , and we have previously identified MMP-9 as a potential target for S-nitrosylation in trophoblast 29 . Thus, we investigated whether elastin uptake was NO-dependent, using the NOS inhibitor L-NAME. In the presence of L-NAME, the percentage of cells containing elastin fragments was significantly reduced after 6h (P<0.01),
but not at any other time points, implying that NO availability is not a prerequisite for elastin uptake.
Identification of candidate elastases in first trimester trophoblasts
To determine the identity of candidate trophoblast elastases, a transcriptomic approach was employed. Affymetrix gene chip analysis of two separate pools of first trimester EVT mRNA (7-10 weeks gestation) demonstrated that caspase-2, MMP-2 and MMP-12 were the most highly expressed protease transcripts ( Table 1 ). The role of MMP-2 in migration and invasion of first trimester EVT has been well characterised previously 20 ; however, the role of MMP-12 (macrophage metalloelastase) in trophoblast function has not been investigated.
MMP-12 mediates elastolysis in first trimester trophoblasts
To validate our transcriptomic data, isolated first trimester CTB were immunostained with an antibody to MMP-12, confirming protein expression ( Figure 3A, B) . As previously shown, pre-treatment of individual CTB supernatants (7-12 weeks gestation) with a broad spectrum MMP inhibitor abolished elastase activity (P<0.001; Figure 3C ). Pre-treatment of the same supernatants with a specific inhibitor of MMP-12 (470.1) significantly reduced elastase activity to a mean value of 31.7±10.9% (P<0.05) of control activity, implicating MMP-12 as an important membrane-associated elastase in trophoblast.
Intracellular elastase activity of HASMC is stimulated by elastin fragments
As VSMC-derived elastases have been shown to mediate elastin breakdown during the progression of atherosclerosis and aneurysm, we investigated whether VSMC could contribute to the elastolysis observed during arterial remodelling in pregnancy. Only a small proportion of cultured HASMC exhibited exogenous intracellular elastase activity (4.81%±1.4; n=7); this was unchanged following culture on Matrigel, a collagen IV and laminin-rich extracellular matrix preparation similar in composition to the basement membrane on which VSMC reside in vivo ( Figure 4A ). Similarly, HASMC cultured with CTB-conditioned medium did not exhibit increased elastase activity, suggesting that soluble factors released from trophoblast do not modulate intracellular elastase activity in vitro. As VSMC may be exposed to elastin fragments generated by trophoblast-mediated elastolysis during remodelling in vivo, HASMC were cultured with elastin fibres. This treatment significantly enhanced intracellular elastase activity (P<0.05), suggesting that the presence of elastin fragments in vivo may stimulate elastase production in the arterial wall.
Intracellular elastase activity of HASMC is partially mediated by serine proteases
To identify the intracellular proteases responsible for the observed elastase activity, whilst minimising the amount of elastin introduced into the flow cytometer, HASMC were cultured on elastin-coated plates for 48h and incubated with cell-permeable protease inhibitors for a further 6h. Broad spectrum caspase-, MMP-and cathepsin inhibitors had no effect on intracellular elastase activity ( Figure 4B) ; however, the serine protease inhibitor PMSF reduced activity by approximately 35% (P<0.05; Figure 4C ). Pre-treatment of HASMC with the broad spectrum NOS inhibitor L-NAME or the specific inducible NOS (iNOS) inhibitor 1400W for 24h had no effect on intracellular elastase activity, suggesting that it was not NOdependent.
Membrane-associated elastase activity in HASMC is MMP-dependent
To identify membrane-associated, pericellular or secreted elastases, HASMC supernatants or conditioned medium were incubated with N-succinyl-(L-alanine) 3 -p-nitroanilide. HASMC cultured on plastic exhibited constitutive membrane-associated elastase activity, which was completely inhibited by a broad spectrum MMP inhibitor (P<0.01; Figure 4D ). HASMC cultured on plates coated with elastin did not exhibit an enhancement of elastase activity (0.435 ± 0.16 µg elastase/mg protein (plastic) versus 0.316 ± 0.09 µg elastase/mg protein (elastin), mean±SEM; n=4) and again, activity was completely inhibited by a broad spectrum MMP inhibitor (P<0.05). The broad spectrum caspase inhibitor zVADfmk, the cathepsin inhibitor Z-FG-NHO-BzOMe and the urokinase plasminogen activator (uPA) inhibitor uPA-STOP had no effect. As the MMP inhibitor had no effect on intracellular elastase activity of HASMC, the activity detected in the cell supernatants must be attributable to membraneassociated elastases. Elastase activity present in the conditioned medium of HASMC was below the level of detection (data not shown).
Membrane-associated elastase activity in HASMC is NO-dependent
To investigate whether the activity of elastolytic MMP was NO-dependent, HASMC were pre-treated with L-NAME or the iNOS inhibitor 1400W for 24h, prior to preparation of cell supernatants. Elastase activity was significantly decreased by both inhibitors, indicating that NO availability is necessary for effective MMP function in HASMC (P<0.05; Figure 4E ).
Elastin uptake is MMP-and NO-dependent
To study elastin fragment uptake over time, HASMC were incubated with elastin and monitored by time lapse video-microscopy ( Figure 5A ). When HASMC were cultured with elastin alone, approximately 80% of control cells contained elastin fragments after 24h
( Figure 5B ). Addition of NNGH or L-NAME to the cultures had a marked effect on the kinetics of elastin uptake. Uptake was significantly decreased at 6h, 12h and 24h in the presence of the MMP inhibitor (P<0.01, P<0.001), and at 6h and 12h by L-NAME (P<0.05, P<0.001; Figure 5C ). These data suggest that MMP and NO are required for effective elastin uptake by HASMC.
VSMC express elastolytic MMP in vitro and in vivo
To investigate whether cultured HASMC express MMP-12, immunostaining was used to confirm expression of the active form ( Figure 6A, B) . Membrane-associated elastase activity of HASMC was reduced to a mean value of 23.3±8.7% of control activity following pretreatment of HASMC supernatants with a specific inhibitor of MMP-12 (P<0.05; Figure   6G ). As previously observed, the broad spectrum MMP inhibitor NNGH abolished elastase activity (P<0.001). These data implicate MMP-12 as an important mediator of HASMC elastolysis in vitro.
During pregnancy, invading EVT release soluble factors including FasL and TRAIL, which trigger VSMC apoptosis 41, 42 . To assess whether these factors can alter MMP-12 expression in spiral artery VSMC ex vivo, unremodelled spiral arteries were dissected from myometrial biopsies obtained from healthy pregnant women undergoing caesarean section at term. 
Discussion
Remodelling of uterine spiral arteries during pregnancy involves not only replacement of vascular endothelial cells and VSMC by invading trophoblast, but also structural and functional transformation of the vascular extracellular matrix. To allow a permanent increase in luminal diameter, the internal elastic lamina and medial elastin fibres must be degraded.
Matrix breakdown is mediated in part by the actions of trophoblast-derived proteases, and we now provide evidence that spiral artery VSMC-derived proteases add their own contribution to elastin catabolism.
Primary first trimester CTB can phagocytose elastin in vitro, and exhibit both intracellular and membrane-associated elastase activity. Intracellular activity is partially attributable to caspases in early gestation, but we were unable to identify candidate enzymes beyond 9 weeks, possibly due to functional redundancy of the enzymes involved. Approximately 60-70% of membrane-associated elastase activity was attributable to MMP-12 (macrophage metalloelastase), which is known to act in association with the cell surface 43 ; it is likely that the remaining proportion is mediated by a combination of MMP-2, -7 and -9, which are capable of elastolysis and are expressed by first trimester trophoblast 19, 20 . MMP-12 has previously been implicated as a potential regulator of trophoblast adhesion and migration 44 ;
here we identify MMP-12 as a candidate elastase which is expressed by both interstitial and endovascular trophoblasts in close proximity to spiral arteries in first trimester. Although NO bioavailability is an important regulator of trophoblast function 27, 28 , including MMP-9 activity at the leading edge of migrating cells 29 , phagocytosis of elastin by trophoblast was not reduced in the presence of a NOS inhibitor.
Elastin degradation appears to be a cooperative process, because VSMC also have the capacity to engulf and degrade small particles of elastin using intracellular and membraneassociated enzymes. In vitro, HASMC expressed low endogenous levels of intracellular elastase; however, this was significantly increased following culture with elastin, and was mediated by serine proteases independently of NO bioavailability. In contrast, HASMC exhibited constitutive, membrane-associated elastase activity, which was attributable to MMP and caspases, was significantly reduced by broad spectrum-and iNOS-specific inhibitors, and was not significantly increased following culture with elastin. Phagocytosis of elastin fragments was reduced in the presence of inhibitors of either MMP or NOS. A major fraction of membrane-associated elastase activity in VSMC was attributable to MMP-12; moreover, expression of MMP-12 was induced in the mural VSMC of excised spiral arteries that had been denuded of endothelium and perfused with CTB-conditioned medium. We therefore hypothesise that soluble factors secreted by endovascular EVT upregulate MMP expression in spiral artery VSMC in vivo, which contributes to, or is a consequence of, the alteration in VSMC phenotype observed in actively remodelling vessels 4, 5 . Indeed, the hypertrophy, dedifferentiation, and disruption of medial smooth muscle layers observed in vivo reflects transition from a stable, contractile phenotype towards a more synthetic, proliferative state, a change that has previously been linked to enhanced MMP expression 45 . . EDP can also stimulate quiescent arterial VSMC to adopt a more proliferative phenotype [49] [50] [51] [52] , and promote MMP expression in cancer cell lines [53] [54] [55] . In addition, EDP may regulate NOS activity, as elastin peptides stimulated NO production in coronary artery endothelial cells and cardiomyocyes 56 . Our data support a model whereby trophoblast-mediated breakdown of the elastin within the spiral arteries liberates EDP that promote MMP-12 expression in medial VSMC. EDP may also increase NO production and MMP activity in trophoblasts, establishing a positive feedback mechanism by which EDP production and MMP-12 activity are maintained.
Elastase activity in HASMC, but not CTB, was dependent on NO bioavailability. This is in contrast to previous work showing that NO donors stimulated MMP expression and activity in term CTB, whereas NOS inhibitors reduced it 57, 58 . These conflicting data may be explained by the later gestational age of the cells, or because we were studying elastolysis, rather than collagenolysis, which is primarily mediated by MMP-2 and -9. Nitration of a tyrosine residue in active site of MMP-2 by peroxynitrite 59 or nitrosylation of a critical cysteine residue in MMP-9 60 , by NO and other reactive nitrogen oxides has been shown to promote enzymatic activity. However, cysteine residues in the zinc-tetrathiolate cluster of endothelial NOS (eNOS) and iNOS are susceptible to NO-induced thiol modification, leading to impaired stability of NOS dimers [61] [62] [63] . It is therefore possible that this may limit NO production, reduce elastase activity and impair arterial vasodilatation. However, further work is needed to elucidate the complex mechanisms controlling matrix breakdown and vascular transformation, and to investigate the spatiotemporal interplay between medial VSMC, invasive trophoblast and other cell types present within the placental bed. with first trimester CTB-conditioned medium (50% (v/v)), or elastin fibres (1 mg/ml) for 48h.
Intracellular elastase activity was quantified using a cell-permeable elastase substrate and flow cytometry. Median, (n=3); *p<0.05; Kruskal-Wallis test.
[B] HASMC were cultured on plates coated with elastin fragments for 48h, and were incubated with a vehicle control (DMSO), the broad spectrum caspase inhibitor zVADfmk (50µM), the MMP inhibitor NNGH (50µM) or the cathepsin inhibitor Z-FG-NHO-BzOMe (10µM) for a further 6h. Intracellular elastase activity was determined as above. Median, (n=4).
[C] HASMC were cultured on elastin coated flasks for 48h, then were incubated with a vehicle control (DMSO), the serine protease inhibitor PMSF (10mg/ml; 6h), the NOS inhibitor L-NAME (5mM; 24h) or the iNOS inhibitor 1400W (5µM; 24h). Intracellular elastase activity was determined as above. 
